Briganix 90 mg (Brigatinib) is an advanced oral medication specifically designed for the treatment of ALK-positive non-small cell lung cancer (NSCLC) in adults. Brigatinib is a next-generation tyrosine kinase inhibitor (TKI) that targets the abnormal anaplastic lymphoma kinase (ALK) gene mutation, a key driver of cancer cell growth in some forms of lung cancer. Briganix 90 mg is especially effective…
Caboxen 20 mg , featuring the active ingredient Cabozantinib , is a cutting-edge oral medication designed to treat advanced renal cell carcinoma (RCC) and medical thyroid cancer (MTC). As part of the tyrosine kinase inhibitors (TKI) class, Caboxen targets multiple receptors involved in tumour growth, effectively slowing or stopping cancer progression. With its proven efficacy, Caboxen offers a powerful solution…
Cabozanix (Cabozantinib) is a cutting-edge oral medication designed to treat advanced stages of various cancers, including renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and medullary thyroid cancer (MTC). As a tyrosine kinase inhibitor (TKI), Cabozantinib blocks specific proteins that drive the growth and spread of cancer cells. Available in 20 mg, 60 mg, and 80 mg strengths, Cabozanix is a…
Capmaxen-200MG is a highly effective antibiotic designed to tackle many bacterial infections. With its powerful 200MG formulation, this medication is ideal for treating common infections such as respiratory tract infections, urinary tract infections, and skin infections. Capmaxen-200MG works by inhibiting bacterial growth, allowing your immune system to clear the infection and helping you feel better faster. Whether you’re…
Cerinib 150 mg contains Ceritinib, a powerful targeted therapy specifically designed for the treatment of ALK-positive non-small cell lung cancer (NSCLC). It is an oral medication used to manage advanced stages of lung cancer, particularly in patients whose cancer has spread to other parts of the body (metastatic) and who may have developed resistance to prior treatments. Ceritinib works by…
Crizocent 250mg (Crizotinib) is a highly effective targeted therapy specifically designed to treat advanced non-small cell lung cancer (NSCLC) that is ALK-positive (anaplastic lymphoma kinase) or ROS1-positive. This innovative medication works by blocking the activity of proteins (ALK and ROS1) that promote cancer cell growth, making it an essential treatment for patients with these specific genetic mutations. Crizocent is trusted…
Elbonix 50mg & Elbonix 25mg, containing Eltrombopag, is a revolutionary treatment for patients with chronic immune thrombocytopenia (ITP), a condition where the body's immune system destroys platelets, leading to increased bleeding and bruising risks. Elbonix is also used for patients with aplastic anaemia and chronic hepatitis C-related low platelet counts. This medication helps increase platelet production, reduces the need for…
Elopag 25mg & 50mg, powered by the active ingredient Eltrombopag, is a highly effective oral medication used to treat chronic immune thrombocytopenia (ITP), aplastic anemia, and chronic hepatitis C-related thrombocytopenia. Thrombocytopenia occurs when your platelet count is too low, leading to excessive bruising or bleeding. Elopag works by increasing platelet production, helping to restore a safe platelet level in the…
Hernix 40 mg, containing the active ingredientNeratinib, is a groundbreaking oral medication specifically designed for patients withearly-stage Targeted therapy for her2-positive breast cancer. It reduces the risk of cancer recurrence after initial treatments such as surgery or chemotherapy. As a tyrosine kinase inhibitor (TKI), Hernix targets and blocks specific proteins involved in cancer cell growth, helping prevent the spread and…
Hertinib-40mg (Neratinib) is an advanced oral medication specifically designed to treat early-stage HER2-positive breast cancer in patients who have completed prior trastuzumab-based therapy. As a targeted therapy, Hertinib-40mg works by inhibiting the HER2 protein, which is responsible for the growth and spread of cancer cells. By blocking this protein, Hertinib-40mg helps prevent cancer from returning, offering patients improved outcomes and…
Ibrucent 140 mg (Ibrutinib) is an innovative oral medication used to treat specific types of blood cancers, including Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Waldenström’s Macroglobulinemia (WM). Ibrutinib, the active ingredient in Ibrucent, is a Bruton’s Tyrosine Kinase (BTK) inhibitor. This targeted therapy blocks the activity of BTK proteins, which are crucial for the growth and survival…
Ibrutix 140mg (Ibrutinib) is a breakthrough oral medication used for the treatment of specific blood cancers such as Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Waldenström's Macroglobulinemia (WM). Ibrutinib, the active ingredient in Ibrutix, is a targeted therapy that works by inhibiting Bruton's Tyrosine Kinase (BTK), a protein essential for the growth and survival of cancerous B-cells. By…
